After charting several related moves earlier this year, Boehringer Ingelheim is returning to the antibody-drug conjugate well ...
The Quebec Society of Vascular Sciences (QSVS) is launching a new conversational AI-powered tool, AmelIA, to its Vascular Health Portal, This initiative, developed in partnership with Boehringer ...
Boehringer Ingelheim, which has so far inked at least five hefty partnerships—including its latest one with South Korea’s ...
German family-owned pharma major Boehringer Ingelheim and AimedBio, a Korean biotech company pioneering antibody-drug ...
An individual patient-level meta-analysis shows that tenecteplase, a next-generation thrombolytic, is at least as effective ...
Mergers and acquisitions are not just for Big Pharma. A new report from Leerink Partners takes a stab at identifying the ...
As pharmaphorum reported during ESMO 2025, fresh from a return to oncology with the FDA approval of zongertinib as a ...
Boehringer Ingelheim unveiled its evolved company brand this week, featuring the corporate claim: “Life forward.” The German pharma giant said the claim builds upon the company’s purpose of ...
Boehringer Ingelheim announced an agreement with Quallent Pharmaceuticals, a private label pharmaceutical distributor, to help expand patient access to citrate-free adalimumab-adbm, Boehringer’s ...
INGELHEIM, Germany & SAN DIEGO--(BUSINESS WIRE)--Boehringer Ingelheim today announced the signing of an option to acquire Trutino Biosciences Inc. (the “Transaction”), a San Diego-based biotech ...
INGELHEIM, Germany & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Boehringer Ingelheim announced today a collaborative agreement with Google Quantum AI (Google), focusing on researching and implementing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback